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Hypothesis: EUS-FNA is useful to stage mediastinal lymph nodes in 
patients with malignant mesothelioma
Methods: A prospective two-center study investigated the diagnostic 
yield of EUS-FNA in the mediastinal lymph node staging of pleural 
mesothelioma as compared to surgical staging by cervical mediasti-
noscopy and post-resectional ﬁndings. Selected patients with pleural 
mesothelioma, were staged by spiral-CT, PET scanning, EUS-FNA and 
cervical mediastinoscopy. Patients without mediastinal lymph node 
invasion were treated with induction chemotherapy with 3 cycles of 
cisplatin and pemetrexed. In patients with a radiological respons or 
stable disease, an extrapleural pneumonectomy was performed with 
optional adjuvant radiotherapy. 
Results: Thirty-six patients were registered from June 2004 until Janu-
ary 2007. Data of 22 patients (61%) were available for this abstract. 
This involved 19 males (86%), the median age was 59 years (40-67 
years). Pathological subtypes were 1 sarcomatous, 18 epithelial and 
3 mixed mesotheliomas. EUS-FNA identiﬁed suspicious mediastinal 
lymph node in 9 patients (41%) and demonstrated malignant cells in 
3 (14%). Cervical mediastinoscopy was subsequently performed in 
17 (77%) patients. The results from the mediastinoscopy revealed no 
additional patients with malignant mediastinal lymph node invasion 
(EUS-FNA sensitivity 100%). 
Conclusion: This is the ﬁrst prospective study on the use of EUS-FNA 
in patients with malignant pleural mesothelioma. The prevalence of 
mediastinal lymph node metastasis in these selected mesothelioma 
patients is low. Although this is only a preliminary analysis, EUS-FNA 
appears to have an at least comparable yield as cervical mediastinosco-
py in identifying malignant mediastinal lymph nodes. The ﬁnal analysis 
will be presented at the conference.
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Background: Vascular endothelial growth factor (VEGF) plays a key 
role in mesothelioma biology. High serum VEGF is a negative prognos-
tic factor in mesothelioma patients which is inversely correlated with 
survival. Bevacizumab (Avastin™) is a recombinant humanized mono-
clonal antibody to VEGF. In phase II trials in mesothelioma patients, 
gemcitabine plus cisplatin on a 21-day schedule produces response 
rates of 16% to 26% and yields a median overall survival (OS) of 9.6 to 
13 months. We evaluated the role of adding bevacizumab to gem-
citabine plus cisplatin in a double-blind, placebo-controlled randomized 
phase II trial.
Methods: Eligible patients had unresectable, histologically-conﬁrmed 
mesothelioma; no prior chemotherapy; performance status 0-1; uni-
dimensionally measurable disease; no tumor invasion of major vessels; 
no bleeding or thrombosis. Progression-free survival (PFS) was the 
primary endpoint. Statistics: 90% power to detect a hazard ratio of 
0.57. Patients were stratiﬁed by performance status (0/1) and histology 
(epithelial/other). Gemcitabine 1250 mg/m2 days 1, 8, every 21 days, 
cisplatin 75 mg/m2 day 1 every 21 days, and bevacizumab 15 mg/kg or 
placebo day 1 every 21 days, was given for 6 cycles, then bevacizumab 
or placebo every 21 days until progression. Baseline plasma VEGF 
was measured. 115 patients enrolled from December 2001 to July 2005 
at 11 sites; 108 (GCB/GCP) 53/55 were evaluable. Male 74%/84%; 
median age 62/65 (range 44-78/20-84); performance status 1 55%/47%; 
epithelial 74%/67%, sarcomatoid/biphasic/other 26%/33%; pleural 
93%/91%, peritoneal 8%/7%, tunica vaginalis 0%/2%; thrombocytosis 
40%/40%, leukocytosis 53%/47%.
Results: Cycles administered (GCB/GCP): total 458/424, median 7/6, 
range 1-42/2-39. Median progression-free survival was 6.9/6.0 months 
(HR 0.93, p=0.88). Median overall survival was 15.6/14.7 months 
(p=0.91). 1-year survival was 59%/57%. Best response: complete 
0%/0%, partial 25%/22%, stable disease 51%/60%. Median VEGF 
(N=56) 131/154 pg/ml (range 31-1760/5-1786). Higher VEGF was 
associated with shorter progression-free (p=0.02) and overall survival 
(p=0.0066). Progression-free (p=0.043) and overall survival (p=0.028) 
were signiﬁcantly better for GCB than GCP in those patients with 
baseline VEGF levels at or below the median; in the high VEGF strata 
there were no signiﬁcant differences in PFS (p=0.24) or OS (p=0.90) 
between treatment arms. Toxicities that were statistically signiﬁcantly 
different between treatment arms (p <0.05), any grade, were: alopecia 
60%/38%; epistaxis 62%/24%; hypertension 45%/22%; non-neutrope-
nic infection 15%/4%; proteinuria 62%/47%; stomatitis 23%/7%. There 
were no statistically signiﬁcantly different toxicities grade 3 or greater. 
Conclusion: In mesothelioma patients, adding bevacizumab to gem-
citabine/cisplatin does not yield statistically signiﬁcant differences in 
progression-free survival, overall survival, response, or grade ı toxicity. 
Bevacizumab-treated patients with low VEGF levels had longer pro-
gression-free and overall survival. 
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Background. A major obstacle to successful cancer treatment is the 
resistance of cancer cells to drugs. Tumors may develop drug resis-
tance during the course of treatment (acquired drug resistance) or 
may possess the innate drug resistance that plays a major role in poor 
prognosis. Mesothelioma is an aggressive, asbestos-related cancer 
that is locally invasive and rapidly (7-10 month) fatal. Until recently, 
mesotheliomas were considered to be notoriously chemoresistant 
tumors. Pemetrexed (Alimta®) plus cisplatin regimen changed this 
perception by demonstrating an increase in the response rate up to 45% 
and survival improvement in patients with unresectable mesotheliomas. 
However, along with the drug responsive patients, there was a cohort of 
patients with no positive outcome. Understanding the mechanisms of 
tumor innate drug sensitivity in mesothelioma is crucial for the devel-
opment of effective treatment regimens that may help to overcome both 
innate and acquired resistance.
Methods. We carried out a retrospective study on a cohort of mesothe-
lioma patients who showed or failed to show a strong primary response 
